Insider trading

Period: 120 months Stock: VCYT Plan: Not on a plan × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

172 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

172 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

172 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

172 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
172 decisions over 120 months Remove this filter
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
172 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

172 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
22 May 2026
Wygant Jonathan VP, Chief Accounting Officer
Sold at will
$1.09M 24,000 at 45.40
34.6%
Not planned
10 Nov 2025
Wygant Jonathan VP, Chief Accounting Officer
Sold at will
$215.98K 5,102 at 42.33
11.6%
Not planned
7 Nov 2025
Wygant Jonathan VP, Chief Accounting Officer
Sold at will
$233.93K 5,818 at 40.21
11.7%
Not planned
27 Feb 2025
Leite John Chief Commercial Officer-CLIA
Sold at will
$194.44K 5,746 at 33.84
6.8%
Not planned
3 Dec 2024
Leite John Chief Commercial Officer-CLIA
Sold at will
$45.41K 1,050 at 43.25
1.4%
Not planned
3 Dec 2024
Wygant Jonathan VP, Chief Accounting Officer
Sold at will
$41.45K 956 at 43.36
2.3%
Not planned
27 Nov 2024
Wygant Jonathan VP, Chief Accounting Officer
Sold at will
$215.83K 5,032 at 42.89
10.6%
Not planned
1 Apr 2024
EASTHAM KARIN Director
Sold at will
$216.53K 10,000 at 21.65
23.2%
Not planned
1 Mar 2024
JONES EVAN/ FA Director
Sold at will
$243.60K 10,000 at 24.36
21.0%
Not planned
19 Jul 2023
JONES EVAN/ FA Director · indirect
Sold at will
$93.23K 3,090 at 30.17
8.1%
Not planned
19 Jul 2023
JONES EVAN/ FA Director
Sold at will
$25.26K 838 at 30.14
2.2%
Not planned
18 Jul 2023
JONES EVAN/ FA Director · indirect
Sold at will
$224.62K 7,441 at 30.19
16.3%
Not planned
18 Jul 2023
JONES EVAN/ FA Director
Sold at will
$70.09K 2,324 at 30.16
5.7%
Not planned
17 Jul 2023
JONES EVAN/ FA Director · indirect
Sold at will
$720.11K 23,949 at 30.07
34.4%
Not planned
17 Jul 2023
JONES EVAN/ FA Director
Sold at will
$574.11K 19,095 at 30.07
31.9%
Not planned
30 May 2023
Bhanji Muna Director
Sold at will
$39.88K 1,539 at 25.91
5.9%
Not planned
14 Apr 2023
Sold at will
$749.36K 34,000 at 22.04
44.3%
Not planned
16 Mar 2023
EASTHAM KARIN Director
Sold, plan not stated
$427.04K 18,750 at 22.78
44.4%
15 Mar 2023
Sold, plan not stated
$773.89K 34,000 at 22.76
38.7%
28 Feb 2023
EASTHAM KARIN Director
Sold, plan not stated
$250.00K 10,000 at 25.00
29.9%
17 Jan 2023
Sold, plan not stated 2×
$895.84K 34,000 at 26.35
35.1%
11 Jan 2023
Sold, plan not stated
$1.59M 63,247 at 25.13
50.1%
Sold half or more
14 Dec 2022
JONES EVAN/ FA Director
Sold, plan not stated
$18.08K 600 at 30.13
1.2%
13 Dec 2022
JONES EVAN/ FA Director
Sold, plan not stated 2×
$51.20K 1,667 at 30.71
3.2%
6 Dec 2022
Kennedy Giulia C Chief Scientific & Med Officer
Sold, plan not stated
$27.65K 1,023 at 27.03
1.5%
1 Dec 2022
Anderson Bonnie H Executive Chairwoman
Sold, plan not stated 2×
$2.26M 80,000 at 28.26
55.2%
Sold half or more
11 Nov 2022
JONES EVAN/ FA Director
Sold, plan not stated 2×
$181.36K 6,000 at 30.23
10.3%
11 Nov 2022
Kennedy Giulia C Chief Scientific & Med Officer
Sold, plan not stated
$58.68 2 at 29.34
0.0%
4 Nov 2022
Kennedy Giulia C Chief Scientific & Med Officer
Sold, plan not stated
$25.58K 1,023 at 25.00
1.5%
8 Aug 2022
Anderson Bonnie H Executive Chairwoman · indirect
Sold, plan not stated 2×
$1.23M 45,000 at 27.31
28.6%
5 Aug 2022
Anderson Bonnie H Executive Chairwoman · indirect
Sold, plan not stated
$2.13M 76,917 at 27.71
32.8%
5 Aug 2022
Kennedy Giulia C Chief Scientific & Med Officer
Sold, plan not stated
$27.28K 1,028 at 26.54
1.4%
14 Jun 2022
Holstein Jens Director
Sold, plan not stated
$141.85K 8,720 at 16.27
81.3%
Sold half or more
10 Jun 2022
Stapley Marc Chief Executive Officer
Bought
$980.09K 60,000 at 16.33
60.1%
First buy on file
8 Jun 2022
GORDON KEVIN K Director
Sold, plan not stated
$277.50K 15,000 at 18.50
63.2%
Sold half or more
4 Mar 2022
Kennedy Giulia C Chief Scientific & Med Officer
Sold, plan not stated 3×
$577.78K 23,003 at 25.12
27.3%
17 Dec 2021
EASTHAM KARIN Director
Sold, plan not stated
$225.00K 5,000 at 45.00
36.4%
7 Dec 2021
Kennedy Giulia C Chief Scientific & Med Officer
Sold, plan not stated 2×
$246.36K 6,125 at 40.22
11.3%
6 Dec 2021
Kennedy Giulia C Chief Scientific & Med Officer
Sold, plan not stated 3×
$332.78K 9,232 at 36.05
16.2%
1 Nov 2021
EASTHAM KARIN Director · indirect
Sold, plan not stated 3×
$145.11M 4,400 at 32,978.71
100%
Sold half or more
17 Sep 2021
Anderson Bonnie H Executive Chairwoman · indirect
Sold, plan not stated
$130.48K 2,600 at 50.18
1.2%
10 Sep 2021
Anderson Bonnie H Executive Chairwoman · indirect
Sold, plan not stated
$95.05K 1,900 at 50.03
0.9%
8 Sep 2021
Kennedy Giulia C Chief Scientific & Med Officer
Sold, plan not stated
$46.79K 926 at 50.53
1.8%
7 Sep 2021
Kennedy Giulia C Chief Scientific & Med Officer
Sold, plan not stated 2×
$633.41K 12,531 at 50.55
19.7%
2 Aug 2021
EASTHAM KARIN Director · indirect
Sold, plan not stated 2×
$193.19K 4,400 at 43.91
50.0%
Sold half or more
23 Jun 2021
Kennedy Giulia C Chief Scientific & Med Officer
Sold, plan not stated
$173.91K 4,375 at 39.75
7.8%
4 Jun 2021
Kennedy Giulia C Chief Scientific & Med Officer
Sold, plan not stated 3×
$314.52K 9,081 at 34.63
14.9%
3 Jun 2021
Holstein Jens Director
Bought
$70.39K 2,000 at 35.19
opened
First buy on file
3 May 2021
EASTHAM KARIN Director · indirect
Sold, plan not stated 3×
$213.70K 4,427 at 48.27
33.5%
4 Mar 2021
Kennedy Giulia C Chief Scientific & Med Officer
Sold, plan not stated 9×
$2.57M 52,015 at 49.36
49.2%
Showing 1–50 of 172. Page 1 of 4 Older →